IL150484A0 - Novel colloid synthetic vectors for gene therapy - Google Patents
Novel colloid synthetic vectors for gene therapyInfo
- Publication number
- IL150484A0 IL150484A0 IL15048400A IL15048400A IL150484A0 IL 150484 A0 IL150484 A0 IL 150484A0 IL 15048400 A IL15048400 A IL 15048400A IL 15048400 A IL15048400 A IL 15048400A IL 150484 A0 IL150484 A0 IL 150484A0
- Authority
- IL
- Israel
- Prior art keywords
- gene therapy
- synthetic vectors
- novel colloid
- colloid synthetic
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/14—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by amino groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47530599A | 1999-12-30 | 1999-12-30 | |
PCT/EP2000/013300 WO2001049324A2 (fr) | 1999-12-30 | 2000-12-28 | Nouveaux vecteurs synthetiques colloides destines a la therapie genique |
Publications (1)
Publication Number | Publication Date |
---|---|
IL150484A0 true IL150484A0 (en) | 2002-12-01 |
Family
ID=23887011
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15048400A IL150484A0 (en) | 1999-12-30 | 2000-12-28 | Novel colloid synthetic vectors for gene therapy |
IL150484A IL150484A (en) | 1999-12-30 | 2002-06-27 | Colloid synthetic vectors for gene therapy |
IL207404A IL207404A0 (en) | 1999-12-30 | 2010-08-04 | Novel colloid synthetic vectors for gene therapy |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL150484A IL150484A (en) | 1999-12-30 | 2002-06-27 | Colloid synthetic vectors for gene therapy |
IL207404A IL207404A0 (en) | 1999-12-30 | 2010-08-04 | Novel colloid synthetic vectors for gene therapy |
Country Status (8)
Country | Link |
---|---|
US (1) | US20030166601A1 (fr) |
EP (1) | EP1242609A2 (fr) |
JP (1) | JP2003519199A (fr) |
CN (2) | CN101041079A (fr) |
AU (1) | AU3366901A (fr) |
CA (1) | CA2395636A1 (fr) |
IL (3) | IL150484A0 (fr) |
WO (1) | WO2001049324A2 (fr) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ259399A0 (en) * | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
AU2002348163A1 (en) * | 2001-11-02 | 2003-05-19 | Intradigm Corporation | Therapeutic methods for nucleic acid delivery vehicles |
US6600075B1 (en) * | 2001-11-13 | 2003-07-29 | E. I. Du Pont De Nemours And Company | Process for the preparation of tertiaŕy amines from primary amines and nitriles |
CA2481979A1 (fr) * | 2002-04-11 | 2003-10-16 | Yasushi Taguchi | Peptides chimiquement modifies a l'aide de polyethyleneglycol |
US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
US8057821B2 (en) * | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
US7964571B2 (en) | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
US9505867B2 (en) * | 2005-05-31 | 2016-11-29 | Ecole Polytechmique Fédérale De Lausanne | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
EP2476756A1 (fr) | 2005-06-15 | 2012-07-18 | Massachusetts Institute of Technology | Lipides contenant des amines et utilisations associées |
JP5059312B2 (ja) * | 2005-09-16 | 2012-10-24 | Hoya株式会社 | 高分散性リン酸カルシウム系化合物ナノ粒子及びその製造方法 |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
EP2183297A2 (fr) * | 2007-07-31 | 2010-05-12 | PolyPlus Transfection | Procédé de fabrication de polyéthylèneimine (pei) linéaire à des fins de transfection et pei linéaire obtenue avec un tel procédé |
US9144546B2 (en) | 2007-08-06 | 2015-09-29 | Clsn Laboratories, Inc. | Nucleic acid-lipopolymer compositions |
US20090042825A1 (en) * | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
JP2010538678A (ja) * | 2007-09-18 | 2010-12-16 | イントラドイグム コーポレーション | K−rassiRNA含有組成物及びそれらの使用法 |
US20100280097A1 (en) * | 2007-09-18 | 2010-11-04 | Intradigm Corporation | Compositions comprising hif-1 alpha sirna and methods of use thereof |
US9095568B2 (en) * | 2007-09-26 | 2015-08-04 | Mark Berninger | Therapeutic and vaccine polyelectrolyte nanoparticle compositions |
CN101970687A (zh) * | 2007-11-09 | 2011-02-09 | 东北大学 | 用于体内基因输送的自组装胶束样纳米颗粒 |
CA2717496A1 (fr) * | 2008-03-12 | 2009-09-17 | Intradigm Corporation | Compositions comprenant du siarn notch1 et procedes d'utilisation de celles-ci |
MX353900B (es) * | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
JP5906184B2 (ja) | 2009-06-22 | 2016-04-20 | バーナム インスティテュート フォー メディカル リサーチ | C末端エレメントを有するペプチドおよびタンパク質を使用する方法および組成物 |
RS58405B1 (sr) | 2009-12-01 | 2019-04-30 | Translate Bio Inc | Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima |
US20130011333A1 (en) * | 2010-01-18 | 2013-01-10 | Board Of Regents, The University Of Texas System | Methods and Compositions for Nanoparticle-Mediated Cancer Cell-Targeted Delivery |
CA2793663C (fr) | 2010-03-19 | 2019-03-19 | The Administrators Of The Tulane Educational Fund | Vecteurs d'administration genique polyplexes |
EP2609135A4 (fr) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | Poly(bêta-amino-alcools), leur préparation et utilisations de ceux-ci |
AU2011352204B2 (en) * | 2010-12-29 | 2015-05-21 | Arrowhead Pharmaceuticals, Inc. | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |
WO2012118778A1 (fr) | 2011-02-28 | 2012-09-07 | Sanford-Burnham Medical Research Institute | Peptides car tronqués, procédés et compositions les utilisant |
WO2012135025A2 (fr) | 2011-03-28 | 2012-10-04 | Massachusetts Institute Of Technology | Lipomères conjugués et utilisations associées |
EP2715291A4 (fr) | 2011-05-31 | 2015-10-21 | Airware Inc | Réétalonnage de capteurs de gaz non dispersif à absorption dans l'infrarouge (ndir) sollicités par absorption |
RS59037B1 (sr) | 2011-06-08 | 2019-08-30 | Translate Bio Inc | Kompozicije lipidnih nanočestica i postupci za isporuku irnk |
US10179801B2 (en) | 2011-08-26 | 2019-01-15 | Sanford-Burnham Medical Research Institute | Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides |
US20130072854A1 (en) * | 2011-09-19 | 2013-03-21 | General Electric Company | Microbubble complexes and methods of use |
PE20150041A1 (es) | 2011-10-27 | 2015-01-28 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
WO2013075244A1 (fr) * | 2011-11-24 | 2013-05-30 | Pu Chen | Conception de séquences peptidiques et leur l'utilisation pour l'administration d'arnsi induite par des peptides |
CN102657843A (zh) * | 2012-06-05 | 2012-09-12 | 云南民族大学 | 抗菌肽组合物及其制备方法 |
EP2859102A4 (fr) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | Polynucléotides résistant à la nucléase et leurs utilisations |
JP2015524410A (ja) | 2012-07-18 | 2015-08-24 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | エポキシケトン系プロテアソーム阻害剤のリポソーム組成物 |
WO2014028487A1 (fr) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Lipidoïdes contenant des amines et leurs utilisations |
WO2014153114A1 (fr) * | 2013-03-14 | 2014-09-25 | Fred Hutchinson Cancer Research Center | Compositions et méthodes de modification de cellules à des fins thérapeutiques |
AU2014236396A1 (en) | 2013-03-14 | 2015-08-13 | Shire Human Genetic Therapies, Inc. | Methods for purification of messenger RNA |
EP3446712A1 (fr) | 2013-03-14 | 2019-02-27 | Translate Bio Ma, Inc. | Compositions d'arnm cftr et procédés et utilisations associés |
WO2014179562A1 (fr) | 2013-05-01 | 2014-11-06 | Massachusetts Institute Of Technology | Dérivés de 1,3,5-triazinane-2,4,6-trione et leurs utilisations |
EP3044314B1 (fr) | 2013-07-12 | 2019-04-10 | SeNa Research, Inc. | Procédés et compositions d'interférence pour polymérase d'adn et synthèse d'adn |
US10711106B2 (en) | 2013-07-25 | 2020-07-14 | The University Of Chicago | High aspect ratio nanofibril materials |
US20160228567A1 (en) * | 2013-10-21 | 2016-08-11 | Northeastern University | Hypoxia-Targeted Delivery System for Pharmaceutical Agents |
US11224642B2 (en) | 2013-10-22 | 2022-01-18 | Translate Bio, Inc. | MRNA therapy for argininosuccinate synthetase deficiency |
MX2016005238A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Formulaciones de lipidos para la administracion de acido ribonucleico mensajero. |
EA034103B1 (ru) | 2013-10-22 | 2019-12-27 | Транслейт Био, Инк. | СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
BR112016024632A2 (pt) | 2014-04-25 | 2018-01-30 | Shire Human Genetic Therapies | métodos de purificação de rna mensageiro |
EP3148552B1 (fr) | 2014-05-30 | 2019-07-31 | Translate Bio, Inc. | Lipides biodégradables pour l'administration d'acides nucléiques |
AU2015279968B2 (en) | 2014-06-24 | 2019-11-14 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
WO2016004202A1 (fr) | 2014-07-02 | 2016-01-07 | Massachusetts Institute Of Technology | Lipidoïdes dérivés de polyamine-acide gras et leurs utilisations |
JP6800410B2 (ja) | 2015-06-19 | 2020-12-16 | マサチューセッツ インスティテュート オブ テクノロジー | アルケニル置換2,5−ピペラジンジオン、および、対象または細胞に剤を送達するための組成物におけるそれらの使用 |
US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
JP2020500020A (ja) | 2016-11-14 | 2020-01-09 | ノバルティス アーゲー | 融合誘導性タンパク質minionに関連する組成物、方法、および治療上の使用 |
EP3565535A4 (fr) | 2017-01-05 | 2020-12-30 | Fred Hutchinson Cancer Research Center | Systèmes et procédés pour améliorer l'efficacité d'un vaccin |
MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
WO2018204392A1 (fr) | 2017-05-02 | 2018-11-08 | Stanford Burnham Prebys Medical Discovery Institute | Peptide liant des monocytes/macrophages associés à une tumeur et procédés d'utilisation associés |
MA49138A (fr) | 2017-05-16 | 2020-03-25 | Translate Bio Inc | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
CA3081758A1 (fr) * | 2017-11-06 | 2019-05-09 | Nitto Denko Corporation | Composes fusogenes pour l'administration de molecules biologiquement actives |
CN109055432B (zh) * | 2018-08-16 | 2020-10-13 | 南京科佰生物科技有限公司 | 慢病毒感染试剂及其制备方法与应用 |
AU2019325702A1 (en) | 2018-08-24 | 2021-02-25 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US20220119450A1 (en) | 2019-02-04 | 2022-04-21 | University Of Tartu | Bi-specific extracellular matrix binding peptides and methods of use thereof |
CN111821421B (zh) * | 2020-08-13 | 2021-11-02 | 上海交通大学 | 一种肠道缓释牛初乳海参肽咀嚼片及其制备方法 |
CN115947671B (zh) * | 2022-11-21 | 2023-09-26 | 荣灿生物医药技术(上海)有限公司 | 一种含氨基甲酸酯键的脂质化合物及其应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4482743A (en) * | 1983-07-28 | 1984-11-13 | Texaco Inc. | Hydroxyalkyl bis(dialkylaminoalkyl)amine manufacture |
US5714166A (en) * | 1986-08-18 | 1998-02-03 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates |
US5776894A (en) * | 1988-12-05 | 1998-07-07 | Novartis Ag | Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US6113946A (en) * | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
US5541230A (en) * | 1993-11-05 | 1996-07-30 | Us Health | Therapeutic polyamines |
US5670347A (en) * | 1994-05-11 | 1997-09-23 | Amba Biosciences Llc | Peptide-mediated gene transfer |
US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
FR2722506B1 (fr) * | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5783178A (en) * | 1994-11-18 | 1998-07-21 | Supratek Pharma. Inc. | Polymer linked biological agents |
US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
CA2223088A1 (fr) * | 1995-06-07 | 1996-12-19 | Bob Dale Brown | Nouveaux lipides cationiques a base de carbamate |
CA2223179A1 (fr) * | 1995-06-07 | 1996-12-19 | Bob Dale Brown | Nouveaux lipides cationiques a base d'acide phosphonique |
US6020526A (en) * | 1995-07-21 | 2000-02-01 | Genta, Incorporated | Amide-based cationic lipids |
US5919442A (en) * | 1995-08-11 | 1999-07-06 | Dendritech, Inc. | Hyper comb-branched polymer conjugates |
CA2202928A1 (fr) * | 1995-08-17 | 1997-02-27 | Wilhelmus Everhardus Hennink | Poly(organo)phosphazenes utilisables dans des systemes de transfection de synthese |
AUPN741696A0 (en) * | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
US5980935A (en) * | 1996-05-15 | 1999-11-09 | Kirpotin; Dmitri | Cationic lipids and methods of use therefor |
GB9623051D0 (en) * | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
US5877220A (en) * | 1997-03-06 | 1999-03-02 | Genta, Incorporated | Amide-based oligomeric cationic lipids |
DE19726186A1 (de) * | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6740643B2 (en) * | 1999-01-21 | 2004-05-25 | Mirus Corporation | Compositions and methods for drug delivery using amphiphile binding molecules |
US6780327B1 (en) * | 1999-02-25 | 2004-08-24 | Pall Corporation | Positively charged membrane |
-
2000
- 2000-12-28 AU AU33669/01A patent/AU3366901A/en not_active Abandoned
- 2000-12-28 WO PCT/EP2000/013300 patent/WO2001049324A2/fr active Application Filing
- 2000-12-28 CN CNA2007100913594A patent/CN101041079A/zh active Pending
- 2000-12-28 CA CA002395636A patent/CA2395636A1/fr not_active Abandoned
- 2000-12-28 IL IL15048400A patent/IL150484A0/xx unknown
- 2000-12-28 JP JP2001549690A patent/JP2003519199A/ja active Pending
- 2000-12-28 CN CN00818748A patent/CN1433478A/zh active Pending
- 2000-12-28 EP EP00991644A patent/EP1242609A2/fr not_active Ceased
-
2002
- 2002-06-27 IL IL150484A patent/IL150484A/en not_active IP Right Cessation
- 2002-11-06 US US10/290,406 patent/US20030166601A1/en not_active Abandoned
-
2010
- 2010-08-04 IL IL207404A patent/IL207404A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU3366901A (en) | 2001-07-16 |
CN101041079A (zh) | 2007-09-26 |
US20030166601A1 (en) | 2003-09-04 |
CA2395636A1 (fr) | 2001-07-12 |
WO2001049324A2 (fr) | 2001-07-12 |
WO2001049324A3 (fr) | 2002-06-06 |
IL150484A (en) | 2010-12-30 |
JP2003519199A (ja) | 2003-06-17 |
CN1433478A (zh) | 2003-07-30 |
EP1242609A2 (fr) | 2002-09-25 |
IL207404A0 (en) | 2010-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL207404A0 (en) | Novel colloid synthetic vectors for gene therapy | |
EP1223947A4 (fr) | Vecteurs cibles | |
HUP0105208A3 (en) | Gene therapy-1 | |
IL146332A0 (en) | PrP-LIKE GENE | |
IL148805A0 (en) | Gene transfer vectors | |
GB9906615D0 (en) | Vector | |
GB0025890D0 (en) | Gene therapy | |
GB0008966D0 (en) | Vectors for gene therapy | |
EP1084236A4 (fr) | Nouveaux vecteurs adenoviraux utilises en therapie genique | |
GB9900009D0 (en) | Gene therapy | |
EP1215284A4 (fr) | Gene de type tsg | |
GB0406539D0 (en) | Gene therapy | |
EP1225222A4 (fr) | Nouveau gene suppresseur des tumeurs | |
GB0112374D0 (en) | Novel protein | |
GB9909446D0 (en) | Vector | |
GB9816775D0 (en) | Herpesviral vectors for gene delivery | |
EP1182256A4 (fr) | Gene 513 associe a la pollinose | |
GB9920837D0 (en) | Gene therapy | |
GB9902522D0 (en) | Truncated vectors | |
GB9903122D0 (en) | Novel gene | |
AU1555P (en) | Maroochy Sundew Fragaria xananassa | |
AU2790P (en) | Diamante Fragaria xananassa | |
AU2789P (en) | Gaviota Fragaria xananassa | |
GB9928539D0 (en) | Novel protein | |
GB9906713D0 (en) | Novel protein |